Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Vinay Prasad, Jeffery A Goldstein

Abstract

Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrollment varied by tumour type, with both over and under-representation occurring. Opportunities to enroll in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.

References

Jun 17, 1999·The New England Journal of Medicine·C P GrossN R Powe
Jun 10, 2004·JAMA : the Journal of the American Medical Association·Vivek H MurthyCary P Gross
May 23, 2006·Lancet·Ida SimTikki Pang
May 3, 2012·JAMA : the Journal of the American Medical Association·Robert M CaliffAsba Tasneem
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph M UngerJohn J Crowley
Mar 26, 2013·Lancet·Hiroto InabaCharles G Mullighan
May 24, 2013·JAMA Internal Medicine·Bradford R HirschAmy P Abernethy
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Aug 20, 2014·Nature Reviews. Clinical Oncology·Andrew M Intlekofer, Anas Younes
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Víctor M Castellano-MegíasFrancisco Colina-Ruizdelgado
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Ambedkar Raj Kulandai VeluIlavarasi Sinduja
Oct 15, 2014·Nature Reviews. Clinical Oncology·Tito Fojo, Paraskevi Giannakakou

❮ Previous
Next ❯

Citations

Oct 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mayra PaolilloSergio Schinelli
Sep 4, 2019·Nature Reviews. Clinical Oncology·Jacob J AdashekRazelle Kurzrock
Nov 7, 2019·The Cochrane Database of Systematic Reviews·Jonathan Livingstone-BanksPeter Hajek
Jan 28, 2016·The Cochrane Database of Systematic Reviews·Daniela C Gonçalves-BradleySasha Shepperd
Oct 20, 2018·BMJ Open·Bilal AlkhaffafAnne-Marie Glenny
Jan 25, 2017·Nature Reviews. Disease Primers·Richard S HotchkissJean-Louis Vincent

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.